By: SUE32073
04 May 2004, 07:25 AM EDT
Msg. 151170 of 151316
(This msg. is a reply to 151064 by mbengineer.)
Jump to msg. #  
mbengineer....Holy smokes, I never really thought you were the former founder and former member of the BOD of ADVR -- Bill Bregman. I have to tell you, it feel really weird having you post on ADVR Stock Message Board. You really have got to be walking on eggs - each and every time - you make a post on here. Did you not sign a Confidentiality Agreement during your time with ADVR? I know you mentioned your "right" to have Freedom of Speech and do as you will since you are not RETIRED. But, the fact is, YOU STILL OWN A CONSIDERABLE AMOUNT OF ADVR SHARES - whether they be in your name of in the name of other family members.

What is YOUR purpose of posting on this rather insane message board? I'm not sure I can come up with a legitimate answer --- I'M STILL IN SHOCK FROM YOUR REVELATION!!!!

P.S. I haven't had a chance to read any of the messages posted last night after your Revelation Post -- I still catching up on here!

By: ricourt0
04 May 2004, 07:41 AM EDT
Msg. 151171 of 151319
Jump to msg. #  
ot AVI BioPharma Presents Additional Data on West Nile Virus Clinical Trial At International Antiviral Conference
Tuesday May 4, 6:45 am ET
First Report of an Antisense Drug Crossing the Blood-Brain Barrier

PORTLAND, Ore.--(BUSINESS WIRE)--May 4, 2004-- AVI BioPharma, Inc. (Nasdaq:AVII - News), today announced that data from its Phase I/II West Nile virus (WNV) clinical trial with its proprietary NEUGENE® antisense drug AVI-4020 showed presence of the drug in cerebrospinal fluid (CSF) of patients treated with AVI-4020. This represents the first report of an antisense drug crossing the blood-brain barrier in a clinical study. The data were presented at the 17th International Conference on Antiviral Research by Patrick L. Iversen, Ph.D., senior vice president of research and development at AVI.
The Phase I/II West Nile virus clinical study was conducted in fall 2003, enrolling 10 patients, nine of whom received AVI-4020 and one of whom received a placebo. The trial was conducted in Colorado at the Boulder Community Medical Center, and was designed to evaluate the safety of AVI-4020. As previously reported by AVI, the study met its primary endpoint, as no safety concerns pertaining to the drug were identified during the trial.

Pharmacokinetic (PK) data from the study showed that the plasma elimination half-life of this third-generation antisense drug was four to five hours. Approximately 24 hours after the last dose of the drug was administered, a spinal tap was done to collect CSF for PK analysis. When the CSF samples were analyzed, all of the patients who received the drug intravenously had drug in the CSF. The mean concentration of the antisense drug was 8.1 nanograms per milliliter (ng/ml) or approximately 1 nanoMolar (nM).

"In addition to the safety results seen in this study, we now have the first evidence of an antisense drug crossing the blood-brain barrier as measured by concentrations in the cerebrospinal fluid of treated patients," Iversen said. "These results open up numerous avenues for development of our NEUGENE compounds in neurological indications, and we plan on further exploring this significant potential in diseases with neurological implications."

"AVI-4020 is a unique drug with the potential to treat West Nile virus, a disease with no existing treatment options," said Nelson Gantz, M.D., chief of Infectious Diseases at the Boulder Community Hospital and an investigator in the study. "In this initial small study, the compound was well tolerated, with no reported drug-related serious adverse events. The results presented show the drug can enter the central nervous system, which appears consistent with the improvement noted in the condition of the patients, and which is an important element in treating viruses, such as West Nile, that may cause brain inflammation. Based on the results to date and the need for new treatments against emerging viruses such as West Nile, AVI-4020 merits further study."


By: BarryAllen
04 May 2004, 09:21 AM EDT
Msg. 151198 of 151319
(This msg. is a reply to 151196 by yanks04.)
Jump to msg. #  
Yanks...Hirschman is finishing out his contract, (12/31/04). Friedland was the only one who knew how to make the drug and he's been gone for 2.5 years. Do you really think Hirschman holds the magic key?

If you would move your butt and visit Hawkins and Epstein in Yonkers, you would take back every word you have said here. Very peculiar that you don't let one post slip by while claiming not to own any stock. What's your agenda Yanks?

(Voluntary Disclosure: Position- Long; ST Rating- Strong Buy)
By: aven2002
04 May 2004, 09:44 AM EDT
Msg. 151201 of 151319
Jump to msg. #  
Hi All,This is from the YAHOO BB...NICE!!...Aven1

From: "draydel" Add to Address Book
Date: Tue, 04 May 2004 13:36:49 -0000
Subject: [Advanced Viral is Reticulose] ADVR will be presnting at an Investor's Conference in NY

On June 5

Nice to see efforts by the company to get their investment story out.

(Voluntary Disclosure: Position- Long; ST Rating- Strong Buy; LT Rating- Strong Buy)

By: nvphyl
04 May 2004, 10:33 AM EDT
Msg. 151229 of 151465
Jump to msg. #  
About the Sunday meeting.

There didn't seem to be much said about the upcoming completion of the Israeli Trial. Back in Nov of 2003 the management seemed to do back-flips over the good pre-lim results. Now la-de-dah?

Then, if I recall, it was said that the new Dr.H was sorting through all the docs one by one. What about the old Dr.H is he lending his full support? Does he even go to the office daily? What about the expensive computer? Any help? I just get this vision of someone sitting at a desk burning the mid-night oil going through box after box of papers looking for something, anything.

Always more questions than answers. That favors traders.

(Voluntary Disclosure: Position- Long)

By: kevtod
04 May 2004, 10:33 AM EDT
Msg. 151230 of 151465
(This msg. is a reply to 151062 by mbengineer.)
Jump to msg. #  
"When asked that question, her reply was that there are two drugs on the market now for that indication and it is unlikely the FDA would fast track another one. She is looking to fast track."

The two Tx refered to for HPV are Aldara & Condylox. We have discussed many times here that the efficacy rate of Aldara hovers around 40%. If the results that are touted in the patent ADVR for HPV (which has since been granted) are to be believed, with efficacy rates of nearly 100%.....this would be a clear improvement to the currently marketed products. Couple this with the often cited low manufacturing cost of AVR118....and, a strong argument could be presented to the FDA for fast track status for this indication.....

BTW.....There are currently at least 3 marketed products for HIV Wasting Syndrome, with several trials for other currently marketed products underway.....

I have said it before & will say it again.....touts of "FAST TRACK STATUS" from management at this juncture has more to do with hyping the shareholders than it has to do with science presentable to the FDA.....

By: lovingitall0
04 May 2004, 12:40 PM EDT
Msg. 151288 of 151465
(This msg. is a reply to 151197 by poppop53.)
Jump to msg. #  
Hi, poppop53: The LiarRarBoston has over 1600 posts here and claims to have no position in ADVR also yet he makes a career out of bashing this stock and others. It's no wonder LiarRar can't earn a living. He has no time left to explore that avenue.

BTW, that p53 at the end of your screen name is a hot topic. A protein that may be crucial for the development of many forms of cancer. Very interesting.

Of course 53 could be just your age, or anything else for that matter. I'm just trying to make a point here how everyone can see and read things differently.

Unfortunately, this used to be an informative Board. Now it's taken over by a bashing group of frustrated wannabees. Every now and then the decent shareholders, like you are, voice opinions and are taken seriously by others.

Best of luck to you. Anyone here since 1986 deserves respect.

By: poppop53
04 May 2004, 12:58 PM EDT
Msg. 151292 of 151466
(This msg. is a reply to 151288 by lovingitall0.)
Jump to msg. #  
thank you for a most articulate reply. You are so right this board has been taken over my some stange people and its a shame.I wish all the shareholders good luck and hope this board could return to serious investors.
- - - - -
View Replies »

By: buckaroobanzai10
04 May 2004, 01:47 PM EDT
Msg. 151298 of 151465
(This msg. is a reply to 151291 by michaelclark11.)
Jump to msg. #  
Mike- Dr. Hawkin' stated intention is to file a new IND with the FDA in 2-3 months. The goal is to get a fast-track application with the FDA. The specific disease for which the drug will be used in these trials was not specified by her.

Apparently, the Phase 2 topical HPV trials on the previously FDA-approved IND will not be done, despite Phase 1 having been successfully completed. The reason given is that this cannot be fast-tracked, and there are other effective drugs out there for the topical treatment of genital warts.

It is still not known if all 30 patients in Israel are enrolled or when those AIDS cachexia trials will be concluded. Hawkins has been hush-hush on this, as she has about the upcoming ASCO presentation. One would assume that if the trials were completed, something would have been said about it in Florida. I presume therefore that they are still continuing and that the 30 patients are not yet completed. If the ASCO presentation next month relates to this study, we will know then.

It is not known if the application of the drug Dr. Hawkins will go for is AIDS cachexia, cancer cachexia or something altogether different. Perhaps even she doesn't quite know yet. However, the only real patient efficacy data in a controlled clinical trial that the company has available to show the FDA is on the AIDS cachexia patients in the Israeli trial. The previous study in AIDS proper carried out in Barbados showed that the drug was marginal at best in fighting the virus directly. In the age of the new effective anti-AIDS HAART drugs, this use of AVR118 would never be fast-tracked by the FDA.

Of course, there could be other options open. Anecdotally, and in patents, the drug has also been touted for diseases as diverse as lymphoma, basal cell carcinoma, boosting red blood cell production, rheumatoid arthritis, multiple sclerosis and canine distemper (a panacea for all ills, it seems). However, in the absence of hard data in proper clinical trials, other than just anecdotal snippets in the patents and patent applications, the FDA may not buy into these applications of the drug. It appears that trials in AIDS or cancer patients who are terminal would be most likely fast-tracked by the FDA.

By: tellslikeitis
04 May 2004, 02:53 PM EDT
Msg. 151313 of 151470
(This msg. is a reply to 151310 by Keith0228.)
Jump to msg. #  
Keith- The name of the game (as it is often played) is that the conference can be as big for you as you want to make it. With the proper spin and hype on the science, and all the anciliary press hoopla one can garner with one's PR firm, anything is possible.

Companies are not "invited" to make specific presentations at ASCO. The members of the American Society of Clinical Oncology (ASCO) are all sent notices (by e-mail or mail) and asked to contribute papers for the annual conference. A member of ASCO (presumably Dr. D'Olimpio) probably sent in an abstract from Advanced Viral, which is what is being presented. A large percentage of contributed abstracts are actually accepted for presentation. I don't believe for a moment(as some here delude themselves) that ASCO pleaded with ADVR with a specific invitation to present its data.

By: Postal
04 May 2004, 03:09 PM EDT
Msg. 151315 of 151471
(This msg. is a reply to 151292 by poppop53.)
Jump to msg. #  
Good Day Pops,
I've been in almost as long as you. Sounds and feels like a prison sentence at times. I think I remember you from the Silicone Investor board. I wonder if you know anything recent of Old Jake Justus. There was a rumor at one time that he died but I think that was denied. On good days he would have a few and then croon on his telephone hotline. I received his newsletter and actually spoke to him a few times. He seemed to be an intelligent gentleman as well as a character. Please let me know if you have any news of him.

Good Luck to all
By: Keith0228
04 May 2004, 03:09 PM EDT
Msg. 151316 of 151467
(This msg. is a reply to 151313 by tellslikeitis.)
Jump to msg. #  
Like you I don't believe ASCO begs anyone for data, but I do believe there would have to be some type of acceptance or approval process in place. ASCO would likely have a finite number of abstracts they can accept/approve, so I guess the next question would be how many submittals are actually made. ADVR could still be in the elite part of the class if say only 50% of 10,000 submittals were accepted. I'm only guessing, but isn't that what we're all doing?

By: lovingitall0
04 May 2004, 03:27 PM EDT
Msg. 151321 of 151473
(This msg. is a reply to 151315 by Postal.)
Jump to msg. #  
Postal, hey you're another old timer from the ADVR Silicon Investor board. Those were the good old days of fun without the bash.

Please don't leave us. We need you guys here.

By: poppop53
04 May 2004, 03:40 PM EDT
Msg. 151323 of 151474
(This msg. is a reply to 151315 by Postal.)
Jump to msg. #  
jake justus a golden name out of the past.I heard he died a few years ago as did john holmes. Do you rember john he had this stock rockin and had he lived we would have seen more than the1.95 high. i had very cheap warrants because of him.jake was something else a real down home southern character who loved a few adult beverages while he talked up advl. we have a pornographic klown and schoolboys who carry on like idiots boy has this board come down.I never got involved with the silicone investor board so im innocent of all charges there. nice hearing from you and if i can be of any help to you you can always catch me on mxdy or cirt. regards mark
- - - - -
By: tellslikeitis
04 May 2004, 04:08 PM EDT
Msg. 151330 of 151474
(This msg. is a reply to 151328 by anna_mny.)
Jump to msg. #  
Since the ASCO abstract for the June 2004 meeting had to be submitted by a December 2003 deadline, it could only have contained data for the first fifteen patients that were completed at that time.
By: Ourobouros
04 May 2004, 09:41 PM EDT
Msg. 151494 of 151885
Jump to msg. #  
Take Emma's name and replace it with Shalom Hirschman's in terms of what HIS focus was back in 1996.

It was to redo the scientific data so that an IND could be filed with the FDA. We were JUST as excited in the focus he had and had announced - and following his IND focus we had a coup,e of poster sessions etc etc.

We all expected great things for the PPS and so on and so on.

So now we have Emma, instead of SZH, the hype remains the same with the same expectations.

In the end, as Sal has said...what is was old is new again.

I'm not sure why anything coming this summer will make much of a difference, much like we expected - but were disappointed - when the last IND and the poster sessions and the microbiology presentations were made.

Maybe I'm stupid, but can you say deja' vu??

By: Ourobouros
04 May 2004, 09:45 PM EDT
Msg. 151495 of 151888
(This msg. is a reply to 151366 by mind31.)
Jump to msg. #  
Why is it that you have an unending string of disputes here.

Are you not satisfied with just the present ones?

Must you start over again with each new poster??

You are turning into a bore, Barry - really!

By: Ourobouros
04 May 2004, 09:51 PM EDT
Msg. 151496 of 151888
(This msg. is a reply to 151381 by shaggydogs.)
Jump to msg. #  
"Jack Justus still walks the face of the earth."

Yes, the last rumor was just that.
By: mbengineer
04 May 2004, 10:01 PM EDT
Msg. 151498 of 151888
Jump to msg. #  
The Istael gov. allowed 30 patients for this study. 23 patients were used. the results will be with 23 patients which will give very satisfactory statistical results. this study is on AIDS. The ASCO is for Cancer.. Lets keep things straight.
By: Ourobouros
04 May 2004, 10:13 PM EDT
Msg. 151499 of 151888
(This msg. is a reply to 151454 by lovingitall0.)
Jump to msg. #  
"They made this forum the absolute disgrace that it is and baited us daily to respond in kind as they got rid of the best posters."

You and son were (and continue to be) just as responsible for the smell here on this board - don't discount your own responsibility for the disgrace here.

By: Ourobouros
04 May 2004, 10:23 PM EDT
Msg. 151500 of 151888
(This msg. is a reply to 151498 by mbengineer.)
Jump to msg. #  
"this study is on AIDS. The ASCO is for Cancer.. Lets keep things straight."

So, Bill, are you saying then that the presentation at ASCO is NOT about the HIV Israeli tests but about "something else?"

I also thought it weird that everyone assumes the HIV tests in Israel are the ones that are going to be presented - but knew the ASCO is a cancer seminar/meeting, which represented to me a dichotomy!
By: nvphyl
04 May 2004, 10:59 PM EDT
Msg. 151502 of 151888
(This msg. is a reply to 151498 by mbengineer.)
Jump to msg. #  
mbengineer, Wow now that is interesting.

By: mbengineer
04 May 2004, 10:01 PM EDT Msg. 151498 of 151500
(Msg. is a reply to by None.)
The Istael gov. allowed 30 patients for this study. 23 patients were used. the results will be with 23 patients which will give very satisfactory statistical results. this study is on AIDS. The ASCO is for Cancer.. Lets keep things straight.

Reading that statement means to me you know that only 23 patients were used. "... 23 patients were used. the results will be with 23 patients..." Were used? Game over, were used!!! From what I know I would have thought the Trial was still in progress.

From the 10K "...Out of 30 total
patients contemplated under the protocol for this study, 23 patients are enrolled, 22 of whom have completed the full course of treatment of AVR118, and one is continuing to receive treatments of AVR118, as required under the study..."

also later in the filing,

"...The completion of the study is dependent upon the availability of patients meeting the prescribed protocol and the ability of the hospitals to meet the requirements of the protocol..."

So if I read what you have wrote to be fact ADVR will not meet the protocol but will use results of an incomplete study using data from the 23 patients instead of the 30 patients described in the protocol.

Now I am not a research scientist but I hope I can follow what is written up to this point. But I don't know the answer to these two questions.

1) How valid will the results be if the protocol is not met?

2) How do you know, as you wrote, "..the results will be with 23 patients..."? Seems like we should all have known that at the same time. I assume I missed the written information.

tia nvp